{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:02:12Z","timestamp":1740157332551,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13181-021-00850-7","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:05:44Z","timestamp":1629140744000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Descriptive Analysis of Inpatient and Outpatient Cohorts Seeking Treatment After Prescription Opioid Misuse and Medical Toxicology Evaluation"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-174X","authenticated-orcid":false,"given":"Shawn M.","family":"Varney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Wax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Brent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On Behalf of the Toxicology Investigators Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"35","key":"850_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.15585\/mmwr.mm6935a1","volume":"69","author":"J O'Donnell","year":"2020","unstructured":"O'Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the district of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189\u201397.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"850_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","volume":"67","author":"L Scholl","year":"2018","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419\u201327.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"850_CR3","unstructured":"CDC. (2019) Opioid overdose. Understanding the epidemic: CDC; [Available from: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html.\u00a0Accessed 10 Jun 2021"},{"key":"850_CR4","unstructured":"Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999-2017. NCHS Data Brief. 2018(329):1\u20138."},{"key":"850_CR5","unstructured":"CDC. (2018) Calculating total daily dose of opioids for safer dosage. [Available from: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/calculating_total_daily_dose-a.pdf.\u00a0Accessed 10 Jun 2021"},{"key":"850_CR6","unstructured":"Organization WH. (2018) Information sheet on opioid overdose: World Health Organization; [Available from: https:\/\/www.who.int\/substance_abuse\/information-sheet\/en\/.\u00a0Accessed 10 Jun 2021"},{"issue":"4","key":"850_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jpain.2015.12.006","volume":"17","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Moore G, Campbell JD, Lodge R, Traugott C, Zerzan J, et al. Risk factors of prescription opioid overdose among Colorado Medicaid beneficiaries. J Pain. 2016;17(4):436\u201343.","journal-title":"J Pain"},{"issue":"23","key":"850_CR8","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","volume":"380","author":"KM Babu","year":"2019","unstructured":"Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"850_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annemergmed.2019.07.014","volume":"75","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Eisenberg M, Schneider KE, Richards TM, Lyons BC, Jackson K, et al. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study. Ann Emerg Med. 2020;75(1):1\u201312.","journal-title":"Ann Emerg Med"},{"key":"850_CR10","unstructured":"HHS.Gov\/opioids. HHS; [Available from: https:\/\/www.hhs.gov\/opioids\/about-the-epidemic\/index.html.\u00a0Accessed 10 Jun 2021"},{"key":"850_CR11","unstructured":"Administration SAaMHS. (2005) substance abuse treatment for persons with co-occurring disorders Treatment Improvement Protocol (TIP) Series, No. 42. In: SAMHSA H, editor. Rockville, MD: Substance Abuse and Mental Health Services Administration; p. 577."},{"issue":"9","key":"850_CR12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7326\/0003-4819-148-9-200805060-00006","volume":"148","author":"LE Sullivan","year":"2008","unstructured":"Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med. 2008;148(9):662\u201370.","journal-title":"Ann Intern Med"},{"key":"850_CR13","unstructured":"Samhsa H. (2018) Buprenorphine waiver management: SAMHSA; [Available from: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/training-materials-resources\/apply-for-practitioner-waiver.\u00a0Accessed 10 Jun 2021"},{"issue":"5","key":"850_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","volume":"73","author":"AA Herring","year":"2019","unstructured":"Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481\u20137.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"850_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13181-019-00728-9","volume":"15","author":"R Marino","year":"2019","unstructured":"Marino R, Perrone J, Nelson LS, Wiegand TJ, Schwarz ES, Wax PM, et al. ACMT position statement: remove the waiver requirement for prescribing buprenorphine for opioid use disorder. J Med Toxicol. 2019;15(4):307\u20139.","journal-title":"J Med Toxicol"},{"key":"850_CR16","unstructured":"Becerra B (2021) Practice guidelines for the administration of buprenorphine for treating opioid use disorder. In: Services HaH, editor. Federal Register: National Archives; p. 22439-40."},{"key":"850_CR17","unstructured":"A. G. The Treatment Gap. New York Times. 2018."},{"issue":"2","key":"850_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s13181-019-00752-9","volume":"16","author":"JE Carpenter","year":"2020","unstructured":"Carpenter JE, Murray BP, Mazer-Amirshahi M, Laes JR, Nacca N, Nelson LS, et al. Leadership roles in opioid stewardship and the treatment of patients with opioid use disorder among medical toxicologists. J Med Toxicol. 2020;16(2):204\u201311.","journal-title":"J Med Toxicol"},{"issue":"4","key":"850_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13181-011-0177-z","volume":"7","author":"PM Wax","year":"2011","unstructured":"Wax PM, Kleinschmidt KC, Brent J, Investigators ATCR. The Toxicology Investigators Consortium (ToxIC) Registry. J Med Toxicol. 2011;7(4):259\u201365.","journal-title":"J Med Toxicol"},{"issue":"4","key":"850_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13181-020-00810-7","volume":"16","author":"MB Spyres","year":"2020","unstructured":"Spyres MB, Farrugia LA, Kang AM, Aldy K, Calello DP, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry-the 2019 Annual Report. J Med Toxicol. 2020;16(4):361\u201387.","journal-title":"J Med Toxicol"},{"issue":"8","key":"850_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/AJP.0b013e318125c5e8","volume":"23","author":"NP Katz","year":"2007","unstructured":"Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648\u201360.","journal-title":"Clin J Pain"},{"issue":"4","key":"850_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13181-012-0266-7","volume":"8","author":"LS Nelson","year":"2012","unstructured":"Nelson LS, Paulozzi LJ. The toxicology Tower of Babel: why we need to agree on a lexicon in prescription opioid research. J Med Toxicol. 2012;8(4):331\u20132.","journal-title":"J Med Toxicol"},{"issue":"3","key":"850_CR23","first-page":"227","volume":"88","author":"JM Tetrault","year":"2015","unstructured":"Tetrault JM, Butner JL. Non-medical prescription opioid use and prescription opioid use disorder: a review. Yale J Biol Med. 2015;88(3):227\u201333.","journal-title":"Yale J Biol Med"},{"issue":"4","key":"850_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","volume":"7","author":"CO Cunningham","year":"2013","unstructured":"Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013;7(4):287\u201393.","journal-title":"J Addict Med"},{"issue":"6","key":"850_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5055\/jom.2007.0018","volume":"3","author":"TJ Cicero","year":"2007","unstructured":"Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302\u20138.","journal-title":"J Opioid Manag"},{"issue":"1","key":"850_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","volume":"39","author":"Z Schuman-Olivier","year":"2010","unstructured":"Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, et al. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abus Treat. 2010;39(1):41\u201350.","journal-title":"J Subst Abus Treat"},{"key":"850_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","volume":"94","author":"SR Kenney","year":"2018","unstructured":"Kenney SR, Anderson BJ, Bailey GL, Stein MD. Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. J Subst Abus Treat. 2018;94:55\u20139.","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"850_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jemermed.2017.03.018","volume":"53","author":"SW Borron","year":"2017","unstructured":"Borron SW, Watts SH, Tull J, Baeza S, Diebold S, Barrow A. Intentional misuse and abuse of loperamide: a new look at a drug with \u201clow abuse potential\u201d. J Emerg Med. 2017;53(1):73\u201384.","journal-title":"J Emerg Med"},{"issue":"5","key":"850_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","volume":"377","author":"CW Goodman","year":"2017","unstructured":"Goodman CW, Brett AS. Gabapentin and pregabalin for pain - is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"850_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.annemergmed.2016.08.444","volume":"69","author":"JP Vakkalanka","year":"2017","unstructured":"Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med. 2017;69(1):73\u20138.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"850_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u201331.","journal-title":"Arch Intern Med"},{"issue":"3","key":"850_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13181-019-00712-3","volume":"15","author":"PM Wax","year":"2019","unstructured":"Wax PM, Stolbach AI, Schwarz ES, Warrick BJ, Wiegand TJ, Nelson LS. ACMT position statement: buprenorphine administration in the emergency department. J Med Toxicol. 2019;15(3):215\u20136.","journal-title":"J Med Toxicol"},{"key":"850_CR33","unstructured":"(2019) Medications for opioid use disorder save lives. Mancher AILaM, editor. Washington, DC: National Academies Press. 156 p."}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-021-00850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T18:31:01Z","timestamp":1632249061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-021-00850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s13181-021-00850-7","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"type":"print","value":"1556-9039"},{"type":"electronic","value":"1937-6995"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}